Search

Background/Objectives: In healthcare environments with high microbial loads, effective infection control measures are critical for reducing airborne and surface contamination. One of the novel modalities in the achievement of these goals is the use of antimicrobial mists, such as droplets, in the form of dry fog. Although the usage of dry fog in the disinfection of contained healthcare microenvironments is well known, the effect of such a system in terms of a meaningful reduction in the microbial burden in an open inpatient ward is unclear. Our objective was to assess the impact of scheduled dry fogging on microbial reduction in such settings. Methods: We collected air and surface samples from rooms receiving daily, biweekly, or no fogging (controls) over six months, establishing the baseline contamination and evaluating the reduction trends in treated rooms. The "reduction effect" was measured by tracking microbial isolation trends before and after treatment, while the "degree of reduction" assessed differences across rooms with varied disinfection schedules. Results: The results indicate that scheduled dry fogging significantly reduced microbial loads in treated rooms, especially with daily disinfection (SE = 64.484, p = 0.002). The airborne contamination in treated rooms showed a strong downward trend over time (SE = 19.192, p < 0.001). Surface contamination remained challenging due to frequent recontamination; however, treated rooms exhibited a consistent reduction in microbial presence (SE = 2.002, p = 0.010), confirming dry fogging's role as a valuable adjunct to routine cleaning. Conclusions: In conclusion, this study highlights that dry fogging effectively reduces microbial loads in open, high-traffic healthcare environments, supporting its use as part of a multimodal infection control strategy. [ABSTRACT FROM AUTHOR]

Background/Objectives: Over the past few decades, extended-spectrum β-lactamase (ESBL)-producing bacteria have become a great concern in healthcare systems worldwide, imposing large burdens by increasing antimicrobial resistance and patient morbidity. Given the high mortality rates and emergence of multidrug-resistant (MDR) strains, monitoring ESBL prevalence and resistance patterns is crucial. This study aimed to evaluate ESBL-producing Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae over three years, focusing on phenotypic distribution and resistance profiles. Methods: A total of 1599 ESBL-producing bacterial samples were collected and analysed. A panel of 20 antibiotics was tested to determine resistance traits. Data were recorded on phenotypical distribution, isolation types, changes in antibiotic resistance, and the relation of such changes to antibiotic consumption (defined daily dose) from clinical isolates. Results: Phenotypical analysis revealed the minimal presence of the Cefotaximase from Munich (CTX-M) phenotype in E. coli and K. pneumoniae, creating a distinct epidemiological profile compared to global patterns. Shifts in isolation trends, particularly in P. mirabilis, suggest an expected increase in associated-mortality-rate in the coming years. While resistance trends were not statistically significant, MDR and extensively drug-resistant (XDR) strains were identified across all three bacteria. Only meropenem showed consistent 100% efficacy against E. coli, with other antibiotics displaying only partial effectiveness. Conclusions: These findings highlight the need for ongoing surveillance of ESBL-producing bacteria and underscore challenges in managing antibiotic resistance due to limited efficacy of last-resort treatments. The unique phenotypical distribution observed could impact local resistance management strategies in hospital settings in the coming years. [ABSTRACT FROM AUTHOR]